Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan in children with recessive dystrophic epidermolysis bullosa
DRKS00009269Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of losartan in dystrophic epidermolysis bullosa (DEB), sponsored by Universitätsklinikum Freiburg. Started Aug 2016; status: completed.
02
Drugs
losartan
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on DRKS00009269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00009269.